HPLF. Competition? No way per this post #654 from Yahoo
From: Donald Date: Tue Nov 25, 2003 7:57 am Subject: Re: [EXTIhead] Don't be concerned about HepaLife - HPLF
Case Closed!!! Thanks.
DS
justskweeznbuy <no_reply@yahoogroups.com> wrote: For those that may be concerned about HepaLife, read this....
A link to this doc is at the bottom of the page.
Later...!
Skw*e~e*znbuy
October 10, 2003
Stocklemon Reports on Hepalife (HPLF) and Patriot Gold (PGOL)
Hide Your Wallets….It's Scott Fraser Time Again….This time he is giving out a 2 for 1 special.
Scott Fraser might be the most indecent newsletter writer in the history of stock promotions. This month Mr. Fraser has crossed the line as he has issued two reports just as the ink is drying on the Securities and Exchange Commission instituted Cease and Desist order. On September 25, 2003, the SEC released order on Scott Fraser and the Natural Contrarian. http://www.sec.gov/litigation/admin/34- 48544.htm
Here are some of the tidbits of the SEC order
"Between August 2001 and November 2001, Fraser wrote and disseminated five materially false and misleading statements"
"Fraser made false and misleading statements concerning the purported returns of his past stock recommendations in solicitation materials"
"False and Misleading Statement Relating to the Financial Success of Subscribers to the Newsletter"
Ok, we admit, knocking Scott Fraser's stocks is too easy. During the past 18 months Stocklemon has profiled 3 stocks covered by Scott Fraser: EYPSF, SBSF, and AOGI. Since Stocklemon profiled these Fraser stocks, they are down an average of 75%. Please see the Stocklemon archives for the stories.
Let us not forget that in 2003 Fraser also recommended ZLNK at $1.. currently trading at .21 cents and EDGH was recommended at .85 cents … currently trading at .22
This month, Scott Fraser brings us two stocks: Patriot Gold (PGOL) and Hepalife (HPLF). Stocklemon has the physical mailed reports mailed by Fraser on each company and Fraser calls each one of these stocks his best stock pick of the year. Instead of reviewing Fraser's reports, which are riddled with lies and exaggerations….yes we said LIES, Stocklemon will go show why each company is a lemon. Thank you Scott for the 2 for 1 special. We will be sure to send you cigarettes if the government ever sends you to jail.
Hepalife (HPLF)
Shares Outstanding- 53,613,332
Market Capitalization- $140,000,000
Cash in Bank- $63,000
Hepalife is a company that is supposed to discover the artificial liver… with $63k in the bank. Scott Fraser was given a budget of over $300k to promote Hepalife in his newsletter.
Hepalife is the latest deal by Vancouver Stock Promoter Harmel Rayat. Mr. Rayat is the majority shareholder of Hepalife. Who is Mr. Rayat? Ask the Securites and Exchange Commission. http://www.sec.gov/litigation/litreleases/lr16662.htm.
HE IS A STOCK PROMOTER
As a matter of fact, the offices of Hepalife are the same offices as were those for EquityAlert.com, Mr. Rayat's promotion company.
For that matter, the offices of Hepalife are shared with four other companies that Harmel Rayat controls. Let's see how these companies are doing so we can guess the fate of HPLF. All of the below companies share the same small office with Hepalife at 1628 West 1st Avenue, Suite 216 Vancouver, CA.
ETHO- .25
ETPT- .24
EDAN- .25
IPTH- .0001
Rayat and family print more paper (to themselves) than the New York Times…or in his case the Vancouver Sun. Mr. Rayat has issued himself and his family TENS of MILLION of S-8 shares of HPLF, options and warrants at an average of $0.07
Who is the new President/CEO?
On September 23, 2003 Hepalife announced that Mr. Arian Soheili is the new President/CEO of Hepalife. Is he a researcher? Is he a Doctor? Is he a liver specialist? No, he is a front man for Harmel Rayat.
Mr. Soheili used to be the treasurer, secretary, and director of Biommune (BIMM)…now trading at .0001. The Rayat family were major shareholders in Biommune. And in order to keep the streak going, Biommune had a dubious history with the SEC for putting out false news to the public.
Hepalife has committed $292,727, over the course of 2 years, to the Dept of Agriculture for a 2 year collaborative research agreement. They only had to put up $97k upon signing of the agreement. Hepalife does not own any technology. This $297k is the total amount that they must provide for the next two years. How much research can really be done for that amount of money? They have not even tested this on animals yet.
More importantly, artificial liver research is currently being performed by well funded organizations and universities throughout the world. No stock promotion, no newsletters, no SEC violations, just real research. Here is a sample list of some research that is years and millions of dollars ahead of Hepalife.
Stocklemon believes that Hepalife is a classic pump and dump that is being orchestrated by a team that is more than familiar with SEC violations. Buyer Beware.
Patriot Gold (PGOL)
The second of the Scott Fraser promotions this month is Patriot Gold. Fraser was given a budget of $416,676 to produce this puff piece for Patriot Gold. Again, the report is riddled with lies about Fraser and his performance. It is so bad that even CBS Marketwatch wrote about the lies that Fraser tells. http://www.marketwatch.com/news/yhoo/story.asp? source=blq/yhoo&siteid=yhoo&dist=yhoo&guid=% 7B032B2ABE%2DE27E%2D4BFD%2DA358%2D4 ACFA5CEDE3D%7D
15.8 million shares outstanding (not including the 13.5 million preferred shares or the 1.4 million warrants)
Market Cap.- $22 million (not including preferred)
Amount paid for mining rights- $12,500
How do you turn $12,500 into $22 million? Just hire Scott (the liar) Fraser. Pay him half million dollars to write a report and watch the magic happen.
Patriot Gold used to be in the business of Ostrich Farming until they ran out of money. But then the management figured why deal with Ostriches when we can deal with gold. Here is a brief timeline of the events in Patriot Gold.
5/1/01 Out of the ostrich business because they did not have any money to continue.
10/20/02 Bruce Johnstone appointed officer and director
10/31/02 The two other directors (Manfred Shultz and Gerald Hinkley) resign as officers and directors of the company.
5/30/03 S-8 filed for 335,000 shares pre-split (of 7.6 or 2.546mm shares)
6/12/03 they issue 13,500,000 Series A 7% Preferred Shares to Bruce Johnstone the company's sole officer and director
6/13/03 Schultz and Hinkley return the 700k shares (for no consideration? And no explanation is given)
6/17/03 forward split of 7.6 for 1 and name and symbol change
7/21/03 Bruce Johnstone resigns as Officer and Director (just over 1 month after receiving 13.5 million preferred shares)
9/23/03 company adds another 3mm shares to the previous 2.546mm that were filed on
C'mon Guys, is this the old mine lease, S8, then newsletter pump and dump? You have got to do better than this. Patriot Gold is not a mining stock. Stocklemon believes Patriot Gold is a scam stock.
Minquest
Patriot Gold acquired this mine lease from a company called Minquest. Minquest provides mining leases to many small companies that are trading under 25 cents. Why should this be any different? We have identified three companies that have acquired leases from Minquest and where they are trading
Who is Patriot the company giving the S8 to? Employee options? THINK NOT. According to their own filings, "We have commenced only limited operations. Therefore, we have no full time employees.
Do not believe us, just read the SEC or the Mark Hulbert report on Scott Fraser. His paid research has done much harm for investors and Stocklemon believes that both Hepalife and Patriot Gold will both face the same fate as the rest of the Fraser lemons.
Disclaimer: Stocklemon.com does not guarantee in any way that it is providing all of the information that may be available. We recommend that you do your own due diligence before buying or selling any security. At any times the princPGOLls of Stocklemon.com might hold a position in any of the securities profiled on the site. Stocklemon.com will not report when a position is initiated or covered. Each investor must make that decision based on his/her judgment of the market.